Standard™ Q COVID-19 Ag Test 2.0
Standard™ Q COVID-19 Ag Test 2.0 is a rapid test for the qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal swabs from individuals suspected of being infected with SARS-CoV-2 by their healthcare provider within the first 6 days of onset of symptoms or from individuals without symptoms or for serial screening. Emergency Use Authorization (EUA) approved.
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigens, which is generally detectable in anterior nasal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definitive cause of disease. All negative results are presumptive and may be confirmed with a molecular assay, if necessary, for patient management. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks. Negative results should be considered in the context of an patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19. Testing of anterior nasal swab specimens is limited to laboratories certified under CLIA that meet the requirements to perform moderate, high, or waived complexity tests. This product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Why Standard™ Q COVID-19 Ag Test 2.0?
Standard Q COVID-19 Ag Test 2.0 offers detection of active infection caused by SARS-CoV-2 in 20 minutes.
- Provides direct detection of SARS-CoV-2 antigens from nasal swabs
- A qualitative immunoassay that offers reliable results in as little as 20 min
- Standard Q COVID-19 Ag Test 2.0 allows for near patient testing without the need of instrumentation or special equipment
Ready to get a handle on COVID-19 testing? Let’s talk.
Related Tests
Related Products
StatID PRO™ COVID-19/Flu A&B
Learn More ⟶
Support & Documents
Downloadable PDFs
FAQs
What sample types can be used?
Nasal Swab sample type can be used with Standard Q COVID-19 Ag Test 2.0
Can samples in transport media be used?
It is not recommended to use transport media with nasal swabs.
Does the Standard Q COVID-19 Ag Test 2.0 kit include External Controls?
Yes, the Standard Q COVID-19 Ag Test 2.0 kit includes 1 positive and 1 negative control swab.
What is the suggested CPT code?
It is suggested to use CPT 87811, and for the CLIA waiver, add a QW designator.
Pricing
- Email: sales@meridianbioscience.com
- Phone: +1 800 696-0739
- International Sales Extension: +1 513 271-3000